オプションチェーンは、Avid Bioservicesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Avid Bioservicesの市場センチメントを評価します。.

Avid Bioservices (NASDAQ:CDMO) 株価情報, オプションチェーン

Avid Bioservices

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.

Avid Bioservices Inc

News

Guidance

WK Kellogg Raises FY24 Adj. EBITDA Guidance; Sees FY24 Adj. EBITDA Growth Of 5%-6%

Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.72) by 11.11 percent. This is a 25.58 percent increase over losses of $(0.86) per share from the same period last year. The company reported quarterly sales of $354.62 million which beat the analyst consensus estimate of $225.00 thousand by 157.51K percent. This is a 110.90K percent increase over sales of $319.47 thousand the same period last year.

Earnings

Earnings Beats

APRE

Aprea Therapeutics Q3 EPS $(0.64) Beats $(0.72) Estimate, Sales $354.62M Beat $225.00K Estimate

Endeavor Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDR#NYSE">EDR</a>) reported quarterly sales of $2.03 billion which beat the analyst consensus estimate of $1.56 billion by 30.29 percent. This is a 51.12 percent increase over sales of $1.34 billion the same period last year.

Endeavor Q3 EPS From Cont. Ops $(0.44), Down From $(0.24) Last Year, Sales $2.03B, Up From $1.22B Prior Year

L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) reported quarterly earnings of $3.27. The company reported quarterly sales of $137.50 million which missed the analyst consensus estimate of $141.78 million by 3.02 percent. This is a 5.40 percent decrease over sales of $145.34 million the same period last year.

Earnings Misses

FSTR

L.B. Foster Q3 2024 GAAP EPS $3.27, Sales $137.50M Miss $141.78M Estimate

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.26 by 19.23 percent. The company reported quarterly sales of $689.000 million which beat the analyst consensus estimate of $674.044 million by 2.22 percent. This is a 0.43 percent decrease over sales of $692.000 million the same period last year.

WK Kellogg Q3 2024 Adj. EPS $0.31 Beats $0.26 Estimate, Sales $689.000M Beat $674.044M Estimate

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Keros Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KROS#NASDAQ">KROS</a>) with a Buy and maintains $100 price target.

Price Target

Reiteration

Analyst Ratings

KROS

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target

HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.42) by 23.81 percent. This is a 35.8 percent increase over losses of $(0.81) per share from the same period last year.

HLVX

HilleVax Q3 EPS $(0.52) Misses $(0.42) Estimate

Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.40) by 15 percent. This is a 8.11 percent increase over losses of $(0.37) per share from the same period last year.

IMNN

Imunon Q3 2024 GAAP EPS $(0.34) Beats $(0.40) Estimate. Cash and Equivalents of $10.3M

Guidance
<ul>
<li>Q4 Consolidated Revenue expected to increase in the high-single digits</li>
<li>Full Year 2024 Consolidated Revenue expected to increase in the mid-single digits</li>
<li>Q4 Consolidated Adjusted EBITDA expected to be approximately $290 million, up approximately 39%</li>
<li>Full Year 2024 Consolidated Adjusted EBITDA expected to be approximately$750 million, up approximately 8%</li>
<li>Full Year 2025 Consolidated Revenue expected to be approximately flat in a non-political year</li>
<li>Full Year 2025 Consolidated Adjusted EBITDA3 expected to be approximately$770 million, up approximately 3% in a non-political year</li>
</ul>

IHRT

iHeartMedia Expects Q4 Revenue Growth Of High-Single Digits Vs $1.00B Est, Reiterated FY24 Revenue Growth Of Mid-Single Digits Vs $3.92B Est, FY25 Revenue Growth Of Approx Flat Vs $3.86B Est

Offerings

BYND

Beyond Meat Files To Offer And Sell Common Stock Having Offering Price Of Up To $20M From Time To Time Through Or To Sales Agent

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the industrials sector.
<h3 class="wp-block-heading">Copa Holdings, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPA#NYSE">CPA</a>)</h3>
<ul>
<li>Dividend Yield: 6.58%</li>
<li>TD Cowen analyst Thomas Fitzgerald maintained a Buy rating and cut the price target from $145 to $130 on Aug. 9. This analyst has an accuracy rate of 61%.</li>
<li>Deutsche Bank analyst Michael Linenberg maintained a Buy rating and slashed the price target from $145 to $130 on Aug. 8. This analyst has an accuracy rate of 75%.</li>
<li>Recent News: Copa Holding will release third-quarter results on Nov. 20.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> latest CPA news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71.png" alt="" class="wp-image-634808" style="width:671px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71-300x272.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042414/image-71-768x697.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Genco Shipping &amp; Trading Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNK#NYSE">GNK</a>)</h3>
<ul>
<li>Dividend Yield: 9.54%</li>
<li>Stifel analyst Benjamin Nolan downgraded the stock from Buy to Hold and cut the price target from $26 to $17 on Oct. 23. This analyst has an accuracy rate of 69%.</li>
<li>B. Riley Securities analyst Liam Burke maintained a Buy rating and increased the price target from $27 to $30 on May 10. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: On Nov. 6, Genco Shipping &amp; Trading posted downbeat quarterly sales.</li>
<li>Benzinga Pro's real-time newsfeed alerted<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> to latest GNK news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72.png" alt="" class="wp-image-634809" style="width:706px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042441/image-72-768x706.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">Karat Packaging Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>)</h3>
<ul>
<li>Dividend Yield: 5.40%</li>
<li>Truist Securities analyst Jake Bartlett downgraded the stock from Buy to Hold rating and cut the price target from $34 to $28 on Aug. 9. This analyst has an accuracy rate of 77%.</li>
<li>Stifel analyst Michael Hoffman reiterated a Buy rating ad increased the price target from $30 to $32 on March 15. This analyst has an accuracy rate of 84%.</li>
<li>Recent News: On Nov. 6, Karat Packaging raised its quarterly dividend from 35 cents to 40 cents per share.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> trend in KRT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73.png" alt="" class="wp-image-634810" style="width:711px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07042612/image-73-768x702.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li>Jim Cramer: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41776764/jim-cramer-this-financial-stock-is-a-buy-likes-broadcom">This Financial Stock Is A Buy, Likes Broadcom</a></li>
</ul>

Dividends

Pre-Market Outlook

Markets

Trading Ideas

Wall Street's Most Accurate Analysts Spotlight On 3 Industrials Stocks With Over 5% Dividend Yields

Biotech

Health Care

General

QNRX

Quoin Had Approximately $10.3M In Cash, Cash Equivalents And Marketable Securities As Of Sept. 30, 2024. This Is Expected To Fund The Company's Operations Into Late 2025

Standard BioTools Inc.&nbsp;("Standard BioTools" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAB#NASDAQ">LAB</a>) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools' finance organization.

Management

Standard BioTools Appoints Alex Kim As Chief Financial Officer, Effective November 11, 2024

OKLO

Oklo Says Department Of Energy And The Idaho National Laboratory Completed Environmental Compliance Process Addressing The DOE Requirements For Site Characterization At Fission Power Plant Site In Idaho

HC Wainwright &amp; Co. analyst Ed Arce reiterates Arbutus Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABUS#NASDAQ">ABUS</a>) with a Buy and maintains $5 price target.

ABUS

HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $5 Price Target

WK Kellogg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported quarterly sales of $689.000 which missed the analyst consensus estimate of $674.044 million by 100.00 percent. This is a 100.00 percent decrease over sales of $692.000 million the same period last year.

WK Kellogg Q3 Sales $689.000 Miss $674.044M Estimate

Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) reported quarterly losses of $(0.47) per share which missed the analyst consensus estimate of $(0.46) by 2.17 percent.

Quoin Pharmaceuticals Q3 2024 GAAP EPS $(0.47) Misses $(0.46) Estimate

MBX Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBX#NASDAQ">MBX</a>) reported quarterly losses of $(2.78) per share. This is a 70.43 percent increase over losses of $(9.40) per share from the same period last year.

MBX Biosciences Q3 EPS $(2.78) Up From $(9.40) YoY

Jim Cramer expressed optimism about a resurgence in mergers and acquisitions (M&amp;A) with the incoming Trump administration. Cramer predicts a more lenient approach to M&amp;A approvals compared to the previous administration, which was known for its stringent antitrust scrutiny.
What Happened: Cramer highlighted that the regional banking sector could significantly benefit from increased M&amp;A activity, allowing banks to grow by acquiring smaller entities or merging to form larger &#8220;super regionals,&#8221; CNBC<a href="https://www.cnbc.com/2024/11/06/jim-cramer-market-for-mergers-and-acquisitions-is-back-under-trump.html"> reported</a> on Thursday.
"I am very confident in the idea that, under President Trump, M&amp;A's about to come back and come back bigly," he said. "Companies will no longer have to fear super-strict antitrust scrutiny, so long as they stay on the right side of our mercurial President elect."
He also suggested that antitrust regulations might be relaxed, potentially benefiting Big Tech companies that faced scrutiny under Biden&#8217;s appointees. However, Cramer warned that Trump&#8217;s personal views could still impact regulatory actions, referencing the 2017 attempt to block the AT&amp;T and Time Warner merger due to Trump&#8217;s issues with CNN.
Cramer noted that several prominent tech CEOs have publicly congratulated Trump, likely in anticipation of a more favorable regulatory environment.
See Also: <a href="https://www.benzinga.com/markets/equities/24/11/41763941/jim-cramer-blasts-super-micro-computers-earnings-better-at-exonerating-itself-than-selling-nvidi?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Jim Cramer Blasts Super Micro Computer&#8217;s Earnings: &#8216;Better At Exonerating Itself Than Selling&#8217; Nvidia GPUs</a>
Why It Matters: The potential revival of M&amp;A under Trump&#8217;s administration aligns with <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41798981/jim-cramer-calls-trumps-return-to-white-house-a-huge-win-for-the-stock-market">Cramer&#8217;s earlier remarks</a> that Trump&#8217;s return to the White House is a &#8220;huge win for the stock market.&#8221; The election of President-elect Trump has brought relief to traders, who anticipate pro-business policies, lower taxes, and deregulation. 
This optimism has already led to record highs in U.S. markets. The market rally <a href="https://www.benzinga.com/markets/asia/24/11/41801023/us-futures-european-stocks-rally-post-trump-victory-while-crude-oil-and-gold-decline-global-markets">post-Trump victory</a> saw the Dow, S&amp;P 500, and Nasdaq surge, with expectations of economic growth under Trump&#8217;s leadership. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41764063/dogecoin-powers-to-7-month-high-as-investors-anticipate-musk-headed-doge-department-under-?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Dogecoin Powers To 7-Month High As Investors Anticipate Musk-Headed DOGE Department Under Trump</a></li>
</ul>
Image via Shutterstock
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noreferrer noopener">Pooja Rajkumari</a>

Jim Cramer Hopes M&A To 'Come Back Bigly' Under Trump Administration

Oppenheimer analyst Jed Kelly upgrades Super Group (SGHC) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) from Perform to Outperform and announces $6 price target.

Upgrades

SGHC

Oppenheimer Upgrades Super Group (SGHC) to Outperform, Announces $6 Price Target

An announcement from Avid Bioservices ( ($CDMO) ) is now available. Avid Bioservices, Inc. has reported a strong start to fiscal 2025 with first-qu...

Avid Bioservices Reports Growth and Strong Pipeline

Avid Bioservices, Inc. (CDMO) Q1 2025 Earnings Call Transcript

In a report released yesterday, Sean Dodge from RBC Capital maintained a Buy rating on Avid Bioservices (CDMO – Research Report), with a price targ...

RBC Capital Sticks to Its Buy Rating for Avid Bioservices (CDMO)

Avid Bioservices stock rallies 18% after reporting increased backlog

Avidity Biosciences: Good Prospects, But We Are A Little Late

Avid Bioservices ( ($CDMO) ) has shared an update. At Avid Bioservices' 2024 Annual Meeting, stockholders approved significant amendments to the 20...

Avid Bioservices' Strategic Shareholder and Governance Updates

16:55 EST Avid Bioservices (CDMO) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breakin...

Avid Bioservices trading halted, news pending

18:35 EST Avid Bioservices (CDMO) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial n...

Avid Bioservices trading resumes

Avid Bioservices (CDMO), GHO Capital Partners LLP and Ampersand Capital Partners announced they have entered into a definitive merger agreement for...

GHO Capital / Ampersand Capital to acquire Avid Bioservices for $12.50 per share

RBC Capital downgraded Avid Bioservices (CDMO) to Sector Perform from Outperform with a price target of $12.50, up from $12, after the company anno...

Comments

Avid Bioservices

Avid Bioservices (CDMO) オプション

Avid Bioservices (NASDAQ:CDMO) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル